{"id":71825,"date":"2026-08-06T14:25:31","date_gmt":"2026-08-06T06:25:31","guid":{"rendered":"https:\/\/flcube.com\/?p=71825"},"modified":"2026-08-06T14:25:32","modified_gmt":"2026-08-06T06:25:32","slug":"astrazeneca-and-cspc-pharmaceutical-establish-joint-venture-for-next-generation-biologics-manufacturing-base-in-shijiazhuang","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71825","title":{"rendered":"AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>AstraZeneca plc<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/AZN:NYSE\">NYSE: AZN<\/a>) and <strong>CSPC Pharmaceutical Group Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/1093:HKG\">HKG: 1093<\/a>) announced the signing of an agreement to establish a <strong>joint venture<\/strong> for building a <strong>next-generation biologics manufacturing base<\/strong> in <strong>Shijiazhuang<\/strong>, further deepening their strategic partnership. The joint venture represents a significant step in AstraZeneca&#8217;s commitment to invest <strong>RMB 100 billion in China by 2030<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-joint-venture-structure\" class=\"wp-block-heading\">Joint Venture Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Location<\/strong><\/td><td>Shijiazhuang, China<\/td><\/tr><tr><td><strong>Equity Ownership<\/strong><\/td><td>CSPC: 51%, AstraZeneca: 49%<\/td><\/tr><tr><td><strong>Governance<\/strong><\/td><td>Joint management and construction oversight<\/td><\/tr><tr><td><strong>Initial Focus<\/strong><\/td><td>Global manufacturing and supply of mutually agreed products<\/td><\/tr><tr><td><strong>Future Expansion<\/strong><\/td><td>Potential portfolio expansion beyond initial products<\/td><\/tr><tr><td><strong>Strategic Alignment<\/strong><\/td><td>Part of AstraZeneca&#8217;s RMB 100 billion China investment commitment by 2030<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-integrated-capabilities-amp-expertise\" class=\"wp-block-heading\">Integrated Capabilities &amp; Expertise<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AstraZeneca Contribution<\/strong>: <strong>Global quality standards<\/strong> and <strong>supply chain management expertise<\/strong> honed through decades of international pharmaceutical operations<\/li>\n\n\n\n<li><strong>CSPC Contribution<\/strong>: <strong>AI-driven GMP manufacturing operations<\/strong> leveraging cutting-edge automation and digital technologies<\/li>\n\n\n\n<li><strong>Combined Vision<\/strong>: Building an <strong>internationally advanced biologics manufacturing base<\/strong> capable of delivering <strong>high-quality medicines to patients worldwide<\/strong><\/li>\n\n\n\n<li><strong>Manufacturing Excellence<\/strong>: Integration of global best practices with local innovation to create a world-class production facility<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-significance\" class=\"wp-block-heading\">Strategic Significance<\/h2>\n\n\n\n<h3 id=\"h-for-astrazeneca\" class=\"wp-block-heading\">For AstraZeneca<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Commitment<\/strong>: Demonstrates strong confidence in deepening presence in China and strengthening collaboration with local partners<\/li>\n\n\n\n<li><strong>Supply Chain Resilience<\/strong>: Enhances global manufacturing capacity and supply chain diversification<\/li>\n\n\n\n<li><strong>Local-Global Integration<\/strong>: Bridges AstraZeneca&#8217;s global standards with China&#8217;s advanced manufacturing capabilities<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-for-cspc-pharmaceutical\" class=\"wp-block-heading\">For CSPC Pharmaceutical<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>International Partnership<\/strong>: Validates CSPC&#8217;s AI-driven manufacturing capabilities on the global stage<\/li>\n\n\n\n<li><strong>Technology Transfer<\/strong>: Access to AstraZeneca&#8217;s world-class quality systems and regulatory expertise<\/li>\n\n\n\n<li><strong>Capacity Expansion<\/strong>: Significant investment in next-generation biologics manufacturing infrastructure<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-broader-implications\" class=\"wp-block-heading\">Market Impact &amp; Broader Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Biologics Manufacturing<\/strong>: The joint venture addresses growing global demand for high-quality biologics manufacturing capacity<\/li>\n\n\n\n<li><strong>China Pharma Ecosystem<\/strong>: Represents continued foreign investment confidence in China&#8217;s pharmaceutical manufacturing capabilities<\/li>\n\n\n\n<li><strong>Innovation Integration<\/strong>: Combines Western quality standards with Chinese AI-driven manufacturing innovation<\/li>\n\n\n\n<li><strong>Patient Access<\/strong>: Enhanced manufacturing capacity will support improved access to biologic medicines globally<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The establishment of this joint venture underscores the evolving nature of global pharmaceutical partnerships, where Western multinationals increasingly collaborate with Chinese companies that have developed world-class manufacturing capabilities, particularly in emerging areas like AI-driven operations.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding joint venture operations, manufacturing capabilities, and strategic investments. Actual results may differ materially due to regulatory approvals, market conditions, operational execution risks, and the inherent uncertainties of large-scale manufacturing projects.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca plc (NYSE: AZN) and CSPC Pharmaceutical Group Limited (HKG: 1093) announced the signing of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[130,171,855,4621],"class_list":["post-71825","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-astrazeneca","tag-cspc-pharmaceutical","tag-hkg-1093","tag-nyse-azn"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AstraZeneca plc (NYSE: AZN) and CSPC Pharmaceutical Group Limited (HKG: 1093) announced the signing of an agreement to establish a joint venture for building a next-generation biologics manufacturing base in Shijiazhuang, further deepening their strategic partnership. The joint venture represents a significant step in AstraZeneca&#039;s commitment to invest RMB 100 billion in China by 2030.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71825\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca plc (NYSE: AZN) and CSPC Pharmaceutical Group Limited (HKG: 1093) announced the signing of an agreement to establish a joint venture for building a next-generation biologics manufacturing base in Shijiazhuang, further deepening their strategic partnership. The joint venture represents a significant step in AstraZeneca&#039;s commitment to invest RMB 100 billion in China by 2030.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71825\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-06T06:25:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-06T06:25:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71825#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71825\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang\",\"datePublished\":\"2026-08-06T06:25:31+00:00\",\"dateModified\":\"2026-08-06T06:25:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71825\"},\"wordCount\":396,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AstraZeneca\",\"CSPC Pharmaceutical\",\"HKG: 1093\",\"NYSE:\u202fAZN\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71825#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71825\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71825\",\"name\":\"AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-06T06:25:31+00:00\",\"dateModified\":\"2026-08-06T06:25:32+00:00\",\"description\":\"AstraZeneca plc (NYSE: AZN) and CSPC Pharmaceutical Group Limited (HKG: 1093) announced the signing of an agreement to establish a joint venture for building a next-generation biologics manufacturing base in Shijiazhuang, further deepening their strategic partnership. The joint venture represents a significant step in AstraZeneca's commitment to invest RMB 100 billion in China by 2030.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71825#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71825\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71825#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang - Insight, China&#039;s Pharmaceutical Industry","description":"AstraZeneca plc (NYSE: AZN) and CSPC Pharmaceutical Group Limited (HKG: 1093) announced the signing of an agreement to establish a joint venture for building a next-generation biologics manufacturing base in Shijiazhuang, further deepening their strategic partnership. The joint venture represents a significant step in AstraZeneca's commitment to invest RMB 100 billion in China by 2030.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71825","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang","og_description":"AstraZeneca plc (NYSE: AZN) and CSPC Pharmaceutical Group Limited (HKG: 1093) announced the signing of an agreement to establish a joint venture for building a next-generation biologics manufacturing base in Shijiazhuang, further deepening their strategic partnership. The joint venture represents a significant step in AstraZeneca's commitment to invest RMB 100 billion in China by 2030.","og_url":"https:\/\/flcube.com\/?p=71825","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-06T06:25:31+00:00","article_modified_time":"2026-08-06T06:25:32+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71825#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71825"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang","datePublished":"2026-08-06T06:25:31+00:00","dateModified":"2026-08-06T06:25:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71825"},"wordCount":396,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AstraZeneca","CSPC Pharmaceutical","HKG: 1093","NYSE:\u202fAZN"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71825#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71825","url":"https:\/\/flcube.com\/?p=71825","name":"AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-06T06:25:31+00:00","dateModified":"2026-08-06T06:25:32+00:00","description":"AstraZeneca plc (NYSE: AZN) and CSPC Pharmaceutical Group Limited (HKG: 1093) announced the signing of an agreement to establish a joint venture for building a next-generation biologics manufacturing base in Shijiazhuang, further deepening their strategic partnership. The joint venture represents a significant step in AstraZeneca's commitment to invest RMB 100 billion in China by 2030.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71825#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71825"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71825#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71825","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71825"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71825\/revisions"}],"predecessor-version":[{"id":71826,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71825\/revisions\/71826"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71825"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71825"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71825"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}